{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T17:05:52Z","timestamp":1779728752697,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10147-026-03010-5","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:39:04Z","timestamp":1776847144000},"page":"968-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of second-line fluorouracil, leucovorin, and irinotecan plus ramucirumab according to prior first-line regimens in metastatic colorectal cancer: a multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Toshinori","family":"Yanagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-8184","authenticated-orcid":false,"given":"Kozo","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"3010_CR1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306\u20131309. https:\/\/doi.org\/10.1126\/science.2479986","journal-title":"Science"},{"key":"3010_CR2","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M et al (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780\u2013787. https:\/\/doi.org\/10.1200\/JCO.2009.23.7537","journal-title":"J Clin Oncol"},{"key":"3010_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15:385\u2013403. https:\/\/doi.org\/10.1038\/nrd.2015.17","journal-title":"Nat Rev Drug Discov"},{"key":"3010_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM et al (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388:518\u2013529. https:\/\/doi.org\/10.1016\/S0140-6736(15)01088-0","journal-title":"Lancet"},{"key":"3010_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0","journal-title":"Lancet Oncol"},{"key":"3010_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101636","volume":"8","author":"H Yasui","year":"2023","unstructured":"Yasui H, Okita Y, Nakamura M et al (2023) Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. ESMO Open 8:101636. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101636","journal-title":"ESMO Open"},{"key":"3010_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003","journal-title":"Ann Oncol"},{"key":"3010_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41:678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690","journal-title":"J Clin Oncol"},{"key":"3010_CR9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M et al (2024) Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:e240029. https:\/\/doi.org\/10.6004\/jnccn.2024.0029","journal-title":"J Natl Compr Canc Netw"},{"key":"3010_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z","journal-title":"Int J Clin Oncol"},{"key":"3010_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF (2014) Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110:551\u2013555. https:\/\/doi.org\/10.1038\/bjc.2013.725","journal-title":"Br J Cancer"},{"key":"3010_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","volume":"102","author":"JM Franklin","year":"2017","unstructured":"Franklin JM, Schneeweiss S (2017) When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther 102:924\u2013933. https:\/\/doi.org\/10.1002\/cpt.857","journal-title":"Clin Pharmacol Ther"},{"key":"3010_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3010_CR14","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Quick Reference 5\u00d77. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed 30 Dec 2025"},{"key":"3010_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"key":"3010_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S et al (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87\u201398. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.007","journal-title":"Eur J Cancer"},{"key":"3010_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K et al (2017) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 3:211\u2013219. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4227","journal-title":"JAMA Oncol"},{"key":"3010_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2018.12.006","volume":"73","author":"G Mauri","year":"2019","unstructured":"Mauri G, Pizzutilo EG, Amatu A et al (2019) Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev 73:41\u201353. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.006","journal-title":"Cancer Treat Rev"},{"key":"3010_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01152-1","volume":"56","author":"LFL da Silva","year":"2024","unstructured":"da Silva LFL, Saldanha EF, da Concei\u00e7\u00e3o LD et al (2024) Anti-EGFR rechallenge in metastatic colorectal cancer and the role of ctDNA: a systematic review and meta-analysis. J Gastrointest Cancer 56:28. https:\/\/doi.org\/10.1007\/s12029-024-01152-1","journal-title":"J Gastrointest Cancer"},{"key":"3010_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-019-03855-w","volume":"84","author":"T Suzuki","year":"2019","unstructured":"Suzuki T, Shinozaki E, Osumi H et al (2019) Second-line FOLFIRI plus Ramucirumab with or without prior Bevacizumab for patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 84:307\u2013313. https:\/\/doi.org\/10.1007\/s00280-019-03855-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"3010_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249\u2013257. https:\/\/doi.org\/10.1038\/35025220","journal-title":"Nature"},{"key":"3010_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58\u201362. https:\/\/doi.org\/10.1126\/science.1104819","journal-title":"Science"},{"key":"3010_CR23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9","journal-title":"Lancet Oncol"},{"key":"3010_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:497\u2013507. https:\/\/doi.org\/10.1016\/S1470-2045(19)30862-9","journal-title":"Lancet Oncol"},{"key":"3010_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41416-020-01089-9","volume":"124","author":"D Rossini","year":"2021","unstructured":"Rossini D, Lonardi S, Antoniotti C et al (2021) Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer 124:183\u2013190. https:\/\/doi.org\/10.1038\/s41416-020-01089-9","journal-title":"Br J Cancer"},{"key":"3010_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.clcc.2020.05.010","volume":"19","author":"AA J\u00e1come","year":"2020","unstructured":"J\u00e1come AA, Kee B, Fogelman D et al (2020) FOLFOXIRI versus doublet regimens in right-sided metastatic colorectal cancer: focus on subsequent therapies and impact on overall survival. Clin Colorectal Cancer 19:248-255.e6. https:\/\/doi.org\/10.1016\/j.clcc.2020.05.010","journal-title":"Clin Colorectal Cancer"},{"key":"3010_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/cam4.3638","volume":"10","author":"H Osumi","year":"2021","unstructured":"Osumi H, Shinozaki E, Ooki A et al (2021) Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer Med 10:615\u2013625. https:\/\/doi.org\/10.1002\/cam4.3638","journal-title":"Cancer Med"},{"key":"3010_CR28","doi-asserted-by":"publisher","first-page":"15219","DOI":"10.18632\/oncotarget.24635","volume":"9","author":"N Fukuda","year":"2018","unstructured":"Fukuda N, Takahari D, Wakatsuki T et al (2018) Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. Oncotarget 9:15219\u201315227. https:\/\/doi.org\/10.18632\/oncotarget.24635","journal-title":"Oncotarget"},{"key":"3010_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241\u2013249. https:\/\/doi.org\/10.1002\/pds.1357","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03010-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03010-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:53:10Z","timestamp":1779727990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03010-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3010"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03010-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8655819\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kataoka K, reports research funding from Sysmex, and honoraria from Eli Lilly, Merck Biopharma, Takeda Pharm, and Guardant Health. Osumi H, reports honoraria from Eli Lilly, Taiho Pharmaceutical, and Merck Serono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}